These IgA PCs secrete IL-10 and express immunomodulatory receptors such as PD-L1 and FAS-L, thereby further inhibiting cytolytic activity [5, 114].These results suggest that cytokine therapies have great potential to modulate B-cell responses and shape the TME to improve cancer treatment outcomes. The gene discussed is CD79A; the disease is cancer.